Galera Therapeutics Announces Presentation of Data from Phase 2b Clinical Trial of Avasopasem Manganese at 2019 NCCN Annual ...
MALVERN, Pa., March 21, 2019 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, today announced …